Redx Pharma (REDX) Reaches New 12-Month Low at $12.00

Redx Pharma PLC (LON:REDX) reached a new 52-week low during trading on Tuesday . The stock traded as low as GBX 12 ($0.17) and last traded at GBX 13 ($0.18), with a volume of 65582 shares trading hands. The stock had previously closed at GBX 13 ($0.18).

The stock has a market cap of $14.09 and a PE ratio of -1,300.00.

In other news, insider Iain Ross bought 102,000 shares of Redx Pharma stock in a transaction that occurred on Friday, December 22nd. The stock was bought at an average cost of GBX 21 ($0.29) per share, with a total value of £21,420 ($29,593.81).

TRADEMARK VIOLATION WARNING: “Redx Pharma (REDX) Reaches New 12-Month Low at $12.00” was reported by Markets Daily and is owned by of Markets Daily. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at

About Redx Pharma

Redx Pharma Plc, formerly Redx Pharma Ltd, is engaged in drug discovery, pre-clinical development and licensing. The Company is engaged in drug discovery across cancer, infection and autoimmune diseases. The Company has over two programs in its oncology research activity, Smoothened Hedgehog (SMO) and Bruton’s Tyrosine Kinase (BTK), which has reached candidate nomination stage.

Receive News & Ratings for Redx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redx Pharma and related companies with's FREE daily email newsletter.

Leave a Reply